Who Owns Novozymes Company?

Novozymes Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Novonesis?

Understanding a company's ownership is key to grasping its strategy and market impact. Novozymes, now Novonesis, a leader in biosolutions, emerged from a demerger with Novo Nordisk in 2000. Its journey began with biological innovation aimed at sustainable solutions.

As of August 2025, Novonesis boasts a market capitalization of approximately $29.15 billion USD, with 2024 revenues reaching $4.148 billion. This robust financial standing is significantly influenced by its primary stakeholder.

The ownership structure of Novonesis is largely defined by the presence of a major philanthropic foundation, which holds a controlling interest. This foundational ownership provides a unique stability and long-term perspective to the company's strategic decisions. The company's commitment to innovation is evident in its diverse product portfolio, including solutions that contribute to a Novozymes PESTEL Analysis.

Public shareholders also play a role, with their investment reflecting confidence in Novonesis's market position and future growth prospects. The company's history is marked by a dedication to biological advancements, stemming from its origins in the 1920s.

The ownership of Novozymes is deeply rooted in its history with Novo Nordisk. Established in 2000, Novozymes emerged from a demerger of Novo Nordisk A/S's enzyme business. The foundational entity, Novo Industri A/S, merged with Nordisk Gentofte in 1989, tracing its origins back to the 1920s with the establishment of Novo Terapeutisk Laboratorium and Nordisk Insulinlaboratorium.

Foundation's Controlling Stake The Novo Nordisk Foundation is the primary and long-term controlling shareholder of Novozymes. This foundation supports scientific, social, and humanitarian endeavors. Holding Company Structure Novo Holdings A/S, a wholly owned subsidiary of the Novo Nordisk Foundation, manages the group's assets. It acts as the central holding company for these investments. Share Capital Holding As of the close of 2024, Novo Holdings A/S held approximately 25.5% of Novozymes' total share capital. This stake represents a significant portion of the company's equity. Voting Rights Control Novo Holdings A/S controls a substantial 63.4% of the voting rights in Novozymes. This control is facilitated by a dual-class share structure. Dual-Class Share Structure Class A shares, held by Novo Holdings A/S, carry ten times the voting power of the publicly traded Class B shares. This structure ensures long-term stability. Founding Vision The dual-class share system reflects the founders' intent to maintain strategic independence and a long-term focus on bioinnovation. This safeguards the company's core mission.

The Novo Nordisk Foundation's substantial voting power, achieved through its ownership of Class A shares, underscores its role in guiding Novozymes' strategic direction and ensuring its continued commitment to innovation. This ownership structure is a key element in understanding Novozymes' corporate governance and its long-term vision, which is further detailed in the Marketing Strategy of Novozymes.

Key Ownership Details

The ownership of Novozymes is characterized by a strong, foundational influence, ensuring stability and a focus on its core business activities.

• Novozymes was established in 2000 via a demerger from Novo Nordisk A/S.
• The Novo Nordisk Foundation is the primary controlling entity.
• Novo Holdings A/S manages the Foundation's assets and holds significant shares.
• At the end of 2024, Novo Holdings A/S held 25.5% of total share capital and 63.4% of voting rights.
• A dual-class share structure (Class A and Class B) is in place.
• Class A shares, held by Novo Holdings A/S, have ten times the voting rights of Class B shares.

Novozymes SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The ownership structure of Novozymes has seen significant shifts, most notably with its merger with Chr. Hansen, which officially formed Novonesis on January 29, 2024. This transaction, valued at $12.3 billion, fundamentally altered the distribution of shares and voting rights within the newly combined entity.

Following the completion of the merger with Chr. Hansen, the ownership of the combined entity, Novonesis, was structured with Novozymes free-float shareholders holding 44% of the total share capital, Chr. Hansen free-float shareholders holding 34%, and Novo Holdings A/S holding 22%. Novo Holdings A/S subsequently increased its stake to 25.5% by the end of 2024, also maintaining a significant 63.4% of the total voting rights. This voting majority is a direct result of the Novo Nordisk Foundation's articles of association, ensuring continued strategic control. Other key institutional investors include BlackRock, Inc. with 4.99%, The Vanguard Group, Inc. with 3.16%, Norges Bank Investment Management with 2.22%, and Pictet Asset Management Limited with 2.03%. These ownership dynamics are central to the company's strategy for accelerated sustainable growth.

Key Stakeholders in Novonesis

Understanding who owns Novozymes, now part of Novonesis, is crucial for grasping its strategic direction. Novo Holdings A/S plays a pivotal role due to its substantial voting power.

• Novo Holdings A/S: Holds 25.5% of share capital and 63.4% of voting rights.
• Novozymes free-float shareholders: Own 44% of the total share capital.
• Chr. Hansen free-float shareholders: Own 34% of the total share capital.
• Major institutional investors include BlackRock, Inc., The Vanguard Group, Inc., Norges Bank Investment Management, and Pictet Asset Management Limited.
• The merger aimed to create a leading biosolutions partner with an estimated annual revenue of €3.7 billion.

Novozymes PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The Board of Directors for Novonesis, formerly Novozymes, is structured to reflect its significant ownership. Cornelis (Cees) de Jong continues as Chair, with Heine Dalsgaard serving as Vice Chair as of April 2025. The board includes members like Lise Kaae, Kasim Kutay, Kevin Lane, Morten Otto Alexander Sommer, and Kim Stratton, joined by new member Monila Kothari.

Novonesis utilizes a dual-class share system, consisting of Class A and Class B shares. As of January 31, 2024, the company had 53,743,600 Class A shares and 414,555,046 Class B shares, totaling 1,903,982,092 voting rights. Class A shares hold ten times the voting power of Class B shares. This structure means Novo Holdings A/S, the primary holder of Class A shares, controlled 63.4% of the total voting rights by the end of 2024, despite holding 25.5% of the share capital. This arrangement ensures substantial and stable influence for the Novo Nordisk Foundation over Novonesis's governance and strategic direction. The company's ownership structure has remained stable, with no significant challenges to its governance model reported recently, underscoring the enduring control by its primary shareholders.

Understanding Novonesis Voting Power

The voting power distribution in Novonesis is heavily influenced by its dual-class share structure. This system is key to understanding Novozymes ownership and who owns Novozymes.

• Class A shares carry significantly more voting power than Class B shares.
• Novo Holdings A/S, representing the Novo Nordisk Foundation, holds a majority of the voting rights.
• This structure ensures long-term strategic alignment and control.
• It provides insight into the Novozymes company structure and Novozymes stock ownership.

Novozymes Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

The ownership landscape of Novozymes has undergone a significant transformation in recent years, primarily driven by its merger with Chr. Hansen. This strategic move has reshaped the shareholder structure and established a new entity with a consolidated market presence.

The merger of Novozymes and Chr. Hansen, finalized on January 29, 2024, created Novonesis, a global biosolutions leader. This all-stock transaction, valued at approximately $12.3 billion, resulted in a new ownership distribution. Initially, Novozymes free-float shareholders held 44%, Chr. Hansen free-float shareholders held 34%, and Novo Holdings A/S held 22% of the combined entity. By the end of 2024, Novo Holdings A/S increased its stake to 25.5%. The combined company aims for organic revenue growth of 6-8% through 2025, reflecting a strong focus on sustainable growth and innovation in the biosolutions sector. Ester Baiget, formerly CEO of Novozymes, now leads Novonesis as President and CEO. The company has also been active in capital management, with plans for share buybacks, including a proposal to renew the authorization to acquire treasury shares up to 10% of the share capital.

Merger Impact on Ownership

The merger with Chr. Hansen has fundamentally altered the Novozymes ownership profile. Novo Holdings A/S has solidified its position as a major shareholder in the newly formed Novonesis.

Capital Management Strategy

Novonesis is actively managing its capital structure through share buyback programs. This strategy aims to enhance shareholder value and optimize the company's financial standing.

Strategic Growth Objectives

The combined entity targets significant organic revenue growth, underscoring a commitment to expanding its market leadership. This focus aligns with broader industry trends towards consolidation and sustainable solutions.

Novo Holdings A/S Role

As a key shareholder, Novo Holdings A/S maintains a controlling interest, ensuring strategic alignment and long-term stability for Novonesis. This commitment reflects its foundational role in the biosolutions sector.

Novozymes Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔